A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1570
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2017 A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. ET, MYSEC-PM, SMF
2017 A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. CALR, ET, PMF
2017 A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm. MPN
2017 A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. AEs, ET, ORR
2017 A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. CV, ECLAP, HU, PHL
2017 After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera. ---
2017 Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. ALOX5
2017 Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study. ---
2017 Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. BM, ET, MPNs, MVD, PMF
10  2017 Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. DXA, ET, HR-pQCT
11  2017 Bumpy road to the diagnosis of polycythaemia vera. ---
12  2017 CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. ET, MPN, PMF
13  2017 Can pegylated interferon improve the outcome of polycythemia vera patients? HU, PEG-IFN
14  2017 Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms. Ang II, Ao, CML, CT-1, ET, MPNs, PMF, STAT
15  2017 Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study. CI, CKD, eGFR, MPNs
16  2017 Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms. EMPs, ET, MPs, Ph-MPN, PMF, PMPs, RMPs
17  2017 Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. ET, MPN, PMF
18  2017 Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms. ET
19  2017 Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms. BID, ET, MEA, MPN, OD, TOR
20  2017 Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera. DM
21  2017 Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. ET, MPNs, PMF
22  2017 Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. ET, MF, MPN, MPNs
23  2017 Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. ET, hs-CRP, MPNs, PTX3
24  2017 Emerging treatments for classical myeloproliferative neoplasms. MPN
25  2017 Experience with ruxolitinib in the treatment of polycythaemia vera. HC, Hct
26  2017 Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. AVWS, ET
27  2017 FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders. CMPD, ET, PMF
28  2017 Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms. ---
29  2017 Genetic Risk Assessment in Myeloproliferative Neoplasms. ET, PMF
30  2017 Histomorphological responses after therapy with pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). BM, ET, MR
31  2017 Imaging features of myeloproliferative neoplasms. CML, ET, MPNs, PMF
32  2017 Incidence and impact of atrial arrhythmias on thrombotic events in MPNs. AA, DOAC, ET, LDA, MPN, VKA
33  2017 Inflammation and myeloproliferative neoplasms. ET, hs-CRP, MF, MPN, PTX-3
34  2017 Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review. CKD, CML, HCL, HCV, HUS, IFN, MS, TMA, TTP
35  2017 Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. ET, HPCs, PMF
36  2017 JAK2 inhibitors for myeloproliferative neoplasms: what is next? MF
37  2017 Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. MPNs
38  2017 Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. BAT, PRO
39  2017 MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. ET, MPN, PMF
40  2017 Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ET, PMF
41  2017 Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm. BMAs, ET, JAK2, MF, MPNs
42  2017 Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. MF, MPNs, RUX
43  2017 MLF1IP promotes normal erythroid proliferation and is involved in the pathogenesis of polycythemia vera. MLF1IP
44  2017 Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender. ET, PMF
45  2017 Monocytosis in polycythemia vera: Clinical and molecular correlates. CMML, MFFS, WHO
46  2017 Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. CMPNs, ET, PMF
47  2017 Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. ET, MF, MPN, RS, SMR
48  2017 NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. ET, MF, MPNs
49  2017 Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. ET, IPF, IRF, MF, MPNs
50  2017 Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. AYA, ET, MF, MPNs
51  2017 Polycythemia causing posterior segment vascular occlusions. CRAO
52  2017 Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. AVWS, ET
53  2017 Polycythemia Vera Management and Challenges in the Community Health Setting. ---
54  2017 Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches. JAK2, MYSEC-PM, PPV-MF
55  2017 Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. ET, HSC, JAK2, MPNs, PMF, PN
56  2017 Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. BM, MFFS, MPN
57  2017 Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature. ET, MPNs, Ph, PMF
58  2017 Progression of primary myelofibrosis to polycythemia vera: A case report. PMF
59  2017 Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications. BM, CFC, EC, ET, PB, Ph- MPN, PMF
60  2017 Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches. JAK2
61  2017 pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms. ET, MPNs, PMF
62  2017 Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera. PH
63  2017 Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with JAK2 Mutation Status. CALR, ET, MPN, PMF
64  2017 Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013. ET, MPNs, PMF
65  2017 Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry. EPO, ET, MPN
66  2017 Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. BAT
67  2017 Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome. BCS, MPNs
68  2017 Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial. BAT, CMR, ET, HC, PMR
69  2017 Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. ET, MPN
70  2017 Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. ET, MPN, TN
71  2017 TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms. ET, MPNs, PMF, SNPs
72  2017 The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation. MF
73  2017 The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium. CALR, ET, JAK2, MPL, MPN, PMF, STAT
74  2017 The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. CALR, DEX, GR, N-CALR, proEry
75  2017 The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). TSS-C
76  2017 The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. ET, MF, MPNs, QOL
77  2017 The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. ---
78  2017 The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes. ET, MGUS, MM, MPN
79  2017 The role of certain gene polymorphisms involved in the apoptotic pathways in polycythemia vera and essential thrombocytosis. ET
80  2017 The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. ET, MF, PMF
81  2017 Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. ET, MPN, PMF
82  2017 Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera. IFN, pegIFNa, TTP
83  2017 Transplant Decisions in Patients with Myelofibrosis: Should Mutations be the Judge? ET, HCT, MPN, PMF
84  2017 VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms. ET, MPNs, PMF
85  2017 Whole-exome sequencing identifies novel candidate predisposition genes for familial polycythemia vera. ---
86  2016 A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera. MF
87  2016 Acquired uniparental disomy of chromosome 9p in hematologic malignancies. aUPD, MPNs
88  2016 Acute Lymphoblastic Leukemia in the Course of Polycythemia Vera: A Case Report and Review of Literature. ALL
89  2016 Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon. ALL, HU
90  2016 Anesthetic management of a patient with polycythemia vera for neurosurgery. ---
91  2016 Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. ET, MPN, NGS, PMF
92  2016 Application of mutant JAK2V617F for in vitro generation of red blood cells. EPO, HSCs, mJAK2, RBCs, wJAK2
93  2016 Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. ET, MPNs, PMF, TNF-alpha
94  2016 Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. ET, MPN, PMF
95  2016 Blood donation and risk of polycythemia vera. CIs, ORs, SIRs
96  2016 Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm. ET, HEMILY, MF, MPN
97  2016 Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. MPN-SAF, PGIC, PSIS, QOL
98  2016 Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. ---
99  2016 Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms ET, Ph-negative MPNs, PMF
100  2016 Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms. ET, HPCs, HSCs, MF, MPN